Allison Moloney – Cellular and Molecular Biology

Dr. Allison Moloney

Dr. Allison Moloney

Moloney, Allison E.


Visiting Assistant Professor of Biology

Biology 207-786-8202Carnegie Science Hall, Room 423

B.S., Biology, Bridgewater State University Ph.D., Cellular and Molecular Medicine, Johns Hopkins University School of Medicine

Courses: Molecular Biology, Emerging and Reemerging Infections Across the Globe, Cancer Biology

Research Interests: My research focuses on the study of how mutated proteins within various signalling pathways allow cancer cells to grow and survive. Many sub-types of cancer possess mutations in receptor tyrosine kinases which lead to uncontrolled proliferation. A class of drugs, tyrosine kinase inhibitors (TKIs), is used to inactivate the signaling capacity of these mutated kinases to cause cancer cell death. However, cancer cells mutate so rapidly and frequently, that many cells develop additional mutations that confer resistance to many of the available TKIs. My research focuses on the characterization of new inhibitors that can overcome these resistant mutant proteins.

Selected Publications:

  • Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M. 2014. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood.  123(1): 94-100.
  • Ma H, Nguyen B, Duffield A, Li L, Galanis A, Williams A, Brown P, Levis M, Leahy D, Small D.2014.  FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Research. 74(18): 5206-5217.
  • Galanis A, Levis M. 2015. Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica. 100(3): e77-e79.
  • Mowafy S, Galanis A, Doctor ZM, Paranal RM, Lasheen DS, Farag NA, Jänne PA, Abouzid KA. 2016. Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives. Bioorganic & Medicinal Chemistry. 22(16): 3501-3512.